CCP
ENZ

Corient Capital Partners’s Enzo Biochem, Inc. ENZ Stock Holding History

Corient Capital Partners’s Portfolio ENZ Stock Details ENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-11,831
Closed -$43K – 488
2019
Q3 		$43K Sell
11,831
-70
-0.6% -$248 0.01% 454
2019
Q2 		$40K Buy
11,901
+569
+5% +$2K 0.01% 404
2019
Q1 		$31K Buy
+11,332
New +$37.1K 0.01% 351

Other funds holding ENZ

HFA
Harbert Fund Advisors Birmingham, Alabama $3.03M AUM 40.55% 1-Year Est. Return
EGA
Evermore Global Advisors Summit, New Jersey $26.3M AUM 7.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FM
Fondren Management Houston, Texas $16.9M AUM 5.82% 1-Year Est. Return

Corient Capital Partners's ENZ Position: Q4 2019 in Review

Corient Capital Partners sold out of Enzo Biochem, Inc. (ENZ) in Q4 2019, closing a stake of 11,831 shares — an estimated $43K sold.

Corient Capital Partners first reported a position in ENZ in Q1 2019 and held it in 3 quarters. The position peaked at $43K in Q3 2019. 81 funds tracked by Wall St. Rank hold ENZ as of Q4 2019.

  • Corient Capital Partners reported no remaining Enzo Biochem, Inc. position as of Q4 2019 after selling out during the quarter.
  • Corient Capital Partners sold 11,831 Enzo Biochem, Inc. shares in Q4 2019, an estimated $43K.
  • Corient Capital Partners first reported a position in Enzo Biochem, Inc. in Q1 2019 and held it in 3 quarters.
  • Corient Capital Partners's Enzo Biochem, Inc. position peaked at $43K in Q3 2019.
  • 81 funds tracked by Wall St. Rank held Enzo Biochem, Inc. as of Q4 2019.

Based on Corient Capital Partners's 13F filing for Q4 2019, filed 4 Feb 2020.